New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:16 EDTAERI, AGNAerie Pharmaceuticals won't be hurt by Allergan move, says RBC Capital
After Allergan (AGN) said it plans to initiate a Phase III trial for its long-acting prostaglandin glaucoma treatment, RBC Capital does not expect Allergan's move to hurt Aerie (AERI), as Aerie's Roclatan has demonstrated statistically significant superiority to a prostaglandin, according to the firm. Moreover, RBC believes that the glaucoma market is large enough to enable multiple products to succeed. It recommends buying Aerie's stock at current levels.
News For AERI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
12:30 EDTAGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 13, 2015
14:00 EDTAGNActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
07:39 EDTAGNAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information
January 12, 2015
14:18 EDTAERIAerie accelerated data read-out a positive, says Cantor
Subscribe for More Information
09:37 EDTAGNSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
08:09 EDTAGNActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTAGNActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
06:31 EDTAERIAerie Pharma accelerates of timeline for reporting results from Rhopressa trial
Aerie Pharmaceuticals announced the acceleration of the expected timeline for reporting efficacy results from the company’s 400-patient Phase 3 registration trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of RhopressaTM compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named “Rocket 3.” Pending the continued advancement of the RhopressaTM Phase 3 program and regulatory approvals, Aerie intends to commercialize RhopressaTM in North American markets and possibly Europe with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use